CO2024001383A2 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- CO2024001383A2 CO2024001383A2 CONC2024/0001383A CO2024001383A CO2024001383A2 CO 2024001383 A2 CO2024001383 A2 CO 2024001383A2 CO 2024001383 A CO2024001383 A CO 2024001383A CO 2024001383 A2 CO2024001383 A2 CO 2024001383A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody formulations
- composition comprises
- example embodiments
- liquid composition
- liquid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 3
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004246 arginine glutamate Drugs 0.000 abstract 1
- 108010013835 arginine glutamate Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan composiciones líquidas que comprenden una concentración alta de un anticuerpo monoclonal, por ejemplo, superior a aproximadamente 100 mg/ml, que demuestran estabilidad de almacenamiento y viscosidad reducida. En realizaciones de ejemplo, la composición líquida comprende aproximadamente menos de aproximadamente 400 mM de glutamato de arginina y, en realizaciones de ejemplo alternativas, la composición líquida comprende prolina y un amortiguador.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232299P | 2021-08-12 | 2021-08-12 | |
| US202263316604P | 2022-03-04 | 2022-03-04 | |
| PCT/US2022/040056 WO2023018870A1 (en) | 2021-08-12 | 2022-08-11 | Antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001383A2 true CO2024001383A2 (es) | 2024-03-07 |
Family
ID=83151728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001383A CO2024001383A2 (es) | 2021-08-12 | 2024-02-08 | Formulaciones de anticuerpos |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR20240046881A (es) |
| AU (1) | AU2022325870A1 (es) |
| CA (1) | CA3228269A1 (es) |
| CO (1) | CO2024001383A2 (es) |
| IL (1) | IL310275A (es) |
| PE (1) | PE20240650A1 (es) |
| TW (1) | TW202319398A (es) |
| WO (1) | WO2023018870A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| MX2018015363A (es) | 2016-06-15 | 2019-04-15 | Amgen Inc | Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. |
| US20200087390A1 (en) * | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2018258676A1 (en) * | 2017-04-28 | 2019-10-31 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| JP2019122373A (ja) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | 抗ｐｄ−１抗体及び治療方法 |
| WO2021079337A1 (en) * | 2019-10-23 | 2021-04-29 | Cadila Healthcare Limited | Pharmaceutical formulation of anti-her2 antibody and preparation thereof |
-
2022
- 2022-08-11 KR KR1020247007623A patent/KR20240046881A/ko unknown
- 2022-08-11 CA CA3228269A patent/CA3228269A1/en active Pending
- 2022-08-11 AU AU2022325870A patent/AU2022325870A1/en active Pending
- 2022-08-11 TW TW111130262A patent/TW202319398A/zh unknown
- 2022-08-11 IL IL310275A patent/IL310275A/en unknown
- 2022-08-11 PE PE2024000233A patent/PE20240650A1/es unknown
- 2022-08-11 WO PCT/US2022/040056 patent/WO2023018870A1/en active Application Filing
-
2024
- 2024-02-08 CO CONC2024/0001383A patent/CO2024001383A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240046881A (ko) | 2024-04-11 |
| WO2023018870A1 (en) | 2023-02-16 |
| TW202319398A (zh) | 2023-05-16 |
| AU2022325870A1 (en) | 2024-02-08 |
| IL310275A (en) | 2024-03-01 |
| PE20240650A1 (es) | 2024-04-04 |
| CA3228269A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111773A1 (es) | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración | |
| ES2569409T3 (es) | Composiciones de anticuerpo anti-CTLA-4 | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| ECSP099642A (es) | Formulaciones estables de anticuerpo | |
| BR122019027966B8 (pt) | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| SV2006002174A (es) | Composicion de anticuerpo her2 | |
| AR117407A1 (es) | Formulaciones acuosas estables de anticuerpos anti-tau | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| EA201200475A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| EA201200204A1 (ru) | Содержащая антитело к her2 композиция для подкожного введения | |
| EA200501692A1 (ru) | Жидкие стабилизированные белковые составы в фармацевтических контейнерах с покрытием | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| CL2023000004A1 (es) | Formulación en concentración alta de proteínas de unión a antígeno del factor xii | |
| CO2024001383A2 (es) | Formulaciones de anticuerpos | |
| BR112022022620A2 (pt) | Formulações de anticorpos anti-il-33 | |
| CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR083338A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) | |
| MX2021012782A (es) | El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion. | |
| CO2022008684A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3 | |
| AR126769A1 (es) | Formulaciones de anticuerpos | |
| AR127813A1 (es) | FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG |